mobic and Rheumatic-Diseases

Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Cyclooxygenase Inhibitors; Humans; Meloxicam; Rheumatic Diseases; Thiazines; Thiazoles

Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Injections, Intramuscular; Meloxicam; Rheumatic Diseases; Thiazines; Thiazoles

Topics: Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Humans; Injections; Intestinal Mucosa; Meloxicam; Rheumatic Diseases; Tablets; Thiazines; Thiazoles

Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Monitoring; Humans; Meloxicam; Rheumatic Diseases; Thiazines; Thiazoles

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Meloxicam; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Rheumatic Diseases; Thiazines; Thiazoles

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-2 without affecting platelet aggregation.. The goal of this study was to assess the efficacy and tolerability of meloxicam under natural prescribing conditions for up to 6 months.. This was a multicenter, prospective, observational cohort study. Participating centers were randomized to 1 of 2 groups: the meloxicam-only group, and the group who received comparator NSAIDs (ie, diclofenac, ibuprofen, piroxicam, or indomethacin).. A total of 4526 patients received either meloxicam (n = 2530) or a comparator NSAID (n = 1996). Treatment groups were comparable in terms of observed efficacy measures. Meloxicam patients had significantly lower rates of reported gastrointestinal (GI) adverse drug reactions (1.80% vs 3.20%; P = 0.003), including dyspepsia (0.08% vs 0.35%; P = 0.049), abdominal pain (0.91% vs 1.90%; P = 0.006), gastritis (0.08% vs 0.60%; P = 0.002), and GI bleeding (0.08% vs 0.50%; P = 0.007), compared with those receiving comparator NSAIDs.. There was evidence that meloxicam was prescribed preferentially to patients who had not responded to NSAIDs previously, who had previously experienced NSAID-induced side effects (and so were at high risk for developing NSAID-induced GI toxicity), or who were more seriously impaired. The nonrandomized and unblinded nature of this study limits the conclusions that can be drawn concerning efficacy or tolerability. Nevertheless, the study results are consistent with the favorable GI tolerability seen with meloxicam in double-blind comparative trials.

Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Male; Meloxicam; Middle Aged; Prospective Studies; Rheumatic Diseases; Risk Factors; Thiazines; Thiazoles; Treatment Outcome

A prospective, randomised comparative clinical study was conducted in adult patients of either sex presenting with articular and non-articular rheumatic conditions commonly encountered in clinical practice Rheumatoid arthritis, osteo-arthritis, cervical spondylosis, and lumbago/sciatica were the most frequent conditions encountered in both the groups, followed by others like tenosynovitis, frozen shoulder, prolapsed disc, fibrositis, myositis, sprains, strains and so on. The drugs that were employed for therapy were diclofenac in a controlled release formulation employing the DRCM technology (subsyde-CR) and meloxicam in a standard formulation marketed in our country. Both drugs were well tolerated and found to be effective in reducing the signs and symptoms of the disease entities throughout the study period, but subsyde-CR was observed to produce a somewhat greater reduction in signs and symptoms scores that meloxicam, a difference that could be possibly attributed to the greater efficacy of subsyde-CR in non-articular rheumatic conditions. On the basis of the available literature on diclofenac and meloxicam as well as the DRCM technology in formulating subsyde-CR, it is reasonable to conclude that a controlled release formulation of diclofenac based on the DRCM technology offers a safe and effective alternative to other non-steroidal anti-inflammatory drugs such as meloxicam.

Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Humans; Male; Meloxicam; Middle Aged; Prospective Studies; Rheumatic Diseases; Thiazines; Thiazoles

Topics: Adrenal Cortex Hormones; Adult; Cross Reactions; Diagnostic Errors; Drug Dosage Calculations; Drug Eruptions; Female; Humans; Hypersensitivity, Delayed; Knee; Medication Errors; Meloxicam; Pruritus Vulvae; Rheumatic Diseases; Skin Tests; Thiazines; Thiazoles

NSAIDs remain the principal pharmacological agents used for symptom relief in patients with rheumatic disease. They represent the largest single group of drugs used worldwide. Given the large number of available NSAIDs, it is unsurprising that some differences exist among them with regard to mechanism of action, pharmacokinetics, and tolerability. How these differences affect the overall risks and benefits of treatment continues to be examined in clinical trials. Meloxicam is COX-2 selective NSAID with favourable gastrointestinal and thromboembolic safety profile.

Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Humans; Meloxicam; Rheumatic Diseases; Thiazines; Thiazoles

Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Tolerance; Humans; Meloxicam; Rheumatic Diseases; Thiazines; Thiazoles

The purpose of the study was to examine the clinical features of the course of coronary heart disease (CHD) in patients with rheumatoid arthritis (RA) and to evaluate the effects of the selective cyclooxygenase-2 (COG-2) inhibitor movalis (meloxicam) in two dosage forms (as injections and tablets) on the course of CHD in this group of patients. The developed questionnaire was used to make a comparative screening survey of 304 patients with RA and 152 patients with osteoarthrosis (OA), who were aged above 40 years. A comprehensive examination of the cardiovascular system was performed in 52 patients with RA concurrent with CHD and 25 patients with OA concurrent with CHD. Angina pectoris on exertion was detected in 37% of the patients with PA and in 35% of the patients with OA. Most (52%) patients with RA and CHD reported rare anginal attacks (once a month) whereas 24-day ECG monitoring revealed myocardial ischemia in 71% of the patients with RA concurrent with CHD; only silent ischemic episodes were recorded in 70% of them. The incidence of silent myocardial ischemia was higher in patients with RA concurrent with CHD than that in those with OA concurrent with CHD (p < 0.03). Examination of the incidence of anginal attacks showed that there was a tendency of the incidence of pains to decrease in patients with RA concurrent with CHD who took selective COG-2 inhibitors. Patients with RA concurrent with CHD who received movalis had atendency of arrhythmia to occur more rarely and of the duration of myocardial ischemia to reduce as compared with those who took nonselective COG-2 inhibitors.

Topics: Administration, Oral; Adult; Aged; Cyclooxygenase Inhibitors; Disease Progression; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Male; Meloxicam; Middle Aged; Myocardial Ischemia; Pain Measurement; Rheumatic Diseases; Thiazines; Thiazoles; Treatment Outcome

Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Humans; Incidence; Meloxicam; Rheumatic Diseases; Thiazines; Thiazoles

Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Humans; Meloxicam; Rheumatic Diseases; Thiazines; Thiazoles